[DISCLOSURE] Genematrix (109820) said on Sept. 29 that it has signed a contract worth 470 million won (US$427,736) with Korea Centers for Disease Control and Prevention for research and development of Zika virus vaccine.

The project will be funded 100 percent by the government and aims to wrap up on Jan. 27, 2019.

By Jung Min-kyung ()